Huglfing, Germany

Elke Faatz

This inventor holds 30 USPTO granted patents and 2 published patent applications, plus 9 CIPO patents and 15 EPO patents, primarily in Immunodiagnostic Technologies. Top assignees: Roche Diagnostics Operations, Inc., Roche Diagnostics Gmbh, Boehringer Mannheim Gmbh. Active years: 1998-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elke Faatz. Retrieved from https://idiyas.com/inventor/elke-faatz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 

% Patents Active = 93.3


 

Average Co-Inventor Count = 4.6

ph-index = 8

Forward Citations = 157(Granted Patents)


Location History:

  • Pahl, DE (1998)
  • Pähl, DE (2003 - 2009)
  • Huglfing, GB (2016)
  • Huglfing, DE (2000 - 2024)

Company Filing History:


Years Active: 1998-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Flavivirus Antibodies
Soluble Antigens
Vitamin D Measurement
Zika Virus NS1
HTLV Capsid Antigen
Fusion Polypeptides
Immunoglobulin Detection
HIV Antigens
Peptidyl Prolyl Isomerase
Rubella E1 Protein
Treponema Pallidum Antigens
Diagnostic Methods
30 patents (USPTO):Explore Patents

Title: Elke Faatz: A Pioneer in Flavivirus and HTLV Antigen Detection

Introduction

Elke Faatz, based in Huglfing, Germany, is a distinguished inventor with an impressive portfolio of 30 patents. His groundbreaking work primarily focuses on the development of innovative methods for detecting antibodies related to flaviviruses and HTLV (Human T-Lymphotropic Virus), significantly contributing to the fields of diagnostics and virology.

Latest Patents

Among his most recent inventions is a method for detecting flavivirus-specific antibodies utilizing flaviviral NS1 polypeptides comprising the wing domain. This invention highlights a polypeptide suitable for detecting antibodies against various flaviviruses, including Zika virus, West-Nile virus, and Dengue virus types 1-4. It specifically emphasizes the absence of amino acid sequences from the NS1 β-ladder domain, enhancing the specificity and efficacy of the detection method. Faatz has also developed soluble and immunoreactive variants of the HTLV capsid antigen P24, which enhances diagnostic applications for detecting antibodies against HTLV-I and HTLV-II in biological samples.

Career Highlights

Faatz has been associated with prominent organizations such as Roche Diagnostics Operations, Inc. and Roche Diagnostics GmbH, where he has made significant contributions to diagnostic innovations. His unique insights and extensive experience have facilitated advancements in the detection methods of various viral infections.

Collaborations

Throughout his career, Elke Faatz has collaborated with notable professionals, including Christian Scholz and Peter Schaarschmidt. These partnerships have amplified the impact of his work, fostering a conducive environment for innovation and research in the biotech sector.

Conclusion

Elke Faatz stands out as a leading inventor in the realms of flavivirus and HTLV diagnostics. His contributions, encapsulated in numerous patents, not only demonstrate his expertise but also inspire ongoing advancements in medical research and diagnostics.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…